full
border
#666666
https://www.arboretumvc.com/wp/wp-content/themes/zap-installable/
https://www.arboretumvc.com/wp/
#ffffff
style1

Archive for March, 2018

22
Mar

BioIQ, a healthcare technology company driving the shift to value-based care, announced today it has raised $26.5M. The financing was led by HealthQuest Capital, with Arboretum Ventures and select insiders joining the syndicate. BioIQ will use the funding to fuel continued growth and support its mission to help transform the U.S. healthcare system and impact more than 100 million lives.

Link

0 Comments
21
Mar

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rezūm® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from of benign prostatic hyperplasia (BPH).

Link

Twin Cities med-tech company NxThera to be sold to Boston Scientific in $400M deal

Twin Cities med-tech company NxThera Inc. has agreed to be sold to Boston Scientific Corp. in a deal worth up to about $400 million, the companies announced Wednesday.
Maple Grove-based NxThera also will spin out a yet-to-be-named startup as part of the deal. The new company will pursue regulatory approval of NxThera’s device as a treatment for prostate cancer, NxThera CEO Bob Paulson said.

Link

0 Comments
16
Mar

NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) platform technology to treat endourological conditions, announced study findings that demonstrate its Rezūm® System provides effective and durable improvements in benign prostatic hyperplasia (BPH) symptom scores with clinical progression rates five times lower when compared to daily, long-term use of pharmaceutical agents three years after treatment.
Download PDF

0 Comments
01
Mar

PEAR Therapeutics announced today that it has entered into a collaboration with Novartis to develop novel prescription digital therapeutics for schizophrenia and multiple sclerosis (MS). These digital therapeutics are software applications designed to effectively improve clinical outcomes for patients. The collaboration brings together Novartis’ expertise in neurological disorders, clinical development, and commercialization with PEAR’s leading experience in prescription digital therapeutic design and implementation.

Download PDF

1
1
scrollauto
Loading posts...
link_magnifier
#ffffff
on
loading
off